Skip to content
10-Q

Quarterly Report

Matinas BioPharma Holdings, Inc. MTNB

0001641172-25-011026

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 15, 2025 5.09M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $2.26M
Current Liabilities Q1 2025 · Dec 31, 2024 $2.67M
Total Liabilities Q1 2025 · Mar 31, 2025 $5.77M
Total Liabilities Q1 2025 · Dec 31, 2024 $5.05M
Current Assets Q1 2025 · Mar 31, 2025 $7.55M
Current Assets Q1 2025 · Dec 31, 2024 $8.03M
Total Assets Q1 2025 · Mar 31, 2025 $12.04M
Total Assets Q1 2025 · Dec 31, 2024 $12.64M
Shares Diluted restated Q1 2025 · Mar 31, 2024 4.35M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$5.77M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $1.07M
Cash And Equivalents Q1 2025 · Dec 31, 2023 $4.79M
Stockholders Equity Q1 2025 · Mar 31, 2024 $14.56M
Stockholders Equity Q1 2025 · Dec 31, 2023 $19.25M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$1.34
Eps Basic restated Q1 2025 · Mar 31, 2024 −$1.34
Sga Expense Q1 2025 · Mar 31, 2024 $2.46M
Rd Expense Q1 2025 · Mar 31, 2024 $3.45M
Net Income Q1 2025 · Mar 31, 2024 −$5.82M
Operating Income Q1 2025 · Mar 31, 2024 −$5.9M